Highest-materiality recent filing
Precigen stockholders approve 7M share increase for 2023 Omnibus Incentive Plan at annual meeting
All nine director nominees elected; Randal Kirk received 207,060,147 votes for, 5,072,069 against.
Precigen Q1: PAPZIMEOS nets $21.6M revenue; loss narrows to $7.9M
Net product revenue from PAPZIMEOS was $21.6M in Q1 2026, first full quarter post-FDA approval.
Precigen posts FY2025 net loss of $1.37/sh; PAPZIMEOS Q4 revenue $3.4M, launch momentum strong
PAPZIMEOS generated $3.4M in net product revenue in Q4 2025, first partial quarter of US commercial sales.
Precigen Reports Q3 2025 Financial Results; PAPZIMEOS Full FDA Approval in August
PAPZIMEOS (zopapogene imadenovec-drba) received full FDA approval in August 2025 for adults with RRP.
Precigen: $79M Preferred Stock converted into 54.9M common shares
Holders converted 79,000 shares of 8.00% Series A Convertible Preferred Stock (stated value $79M) into 54,937,411 common shares.
Precigen secures up to $125M non-dilutive senior secured loan financing from Pharmakon
$100M funded at close; $25M delayed draw available through June 2027; matures Sept 2030.
Precigen enters into commercial supply agreement with Catalent for PAPIZEMOS manufacturing
Agreement dated August 13, 2025 with Catalent Maryland for fill/finish services for gene therapy PAPIZEMOS (PRGN-2012).
Precigen announces FDA approval of PAPZIMEOS (no further details)
US FDA approval of PAPZIMEOS announced via slide deck at August 18, 2025 investor webcast.
Precigen shareholders approve 300M share increase, re-elect directors, and expand equity plans
Increased authorized common shares by 300 million (223.2M votes for).
Precigen Q1 net loss $54.2M; PRGN-2012 BLA under FDA priority review with PDUFA Aug 27
Net loss of $54.2M ($0.18/share) vs $23.7M ($0.10) YoY; includes $32.5M non-cash warrant liability fair value change.
Precigen reports FY2024 net loss of $126M; FDA priority review for PRGN-2012 BLA
FDA accepted BLA for PRGN-2012 with priority review; PDUFA target date Aug 27, 2025.
Precigen regains Nasdaq bid price compliance, delisting risk resolved
Nasdaq notified Precigen on Jan 16, 2025 that it regained compliance with the $1.00 minimum bid price rule.
Precigen completes BLA submission for PRGN-2012 and raises $79M in private placement
Submitted BLA to FDA for PRGN-2012 (RRP), requesting priority review; 60-day review period to determine acceptance.
Precigen sells FCX-007 assets for $8.5M cash, exits Castle Creek collaboration
Asset Acquisition Agreement with Innovator 21 (Paragon affiliate) closed Dec 24, 2024 for $8.5M cash.
Precigen Q3 net loss widens to $24M; on track for Q4 PRGN-2012 BLA submission
Net loss of $24.0M ($0.09/sh) vs $19.8M loss YoY; nine-month loss $106.5M ($0.41/sh).
Precigen receives Nasdaq bid price deficiency notice; has until Apr 30, 2025 to regain compliance
Stock closed below $1 for 30 consecutive business days; compliance deadline April 30, 2025.
Precigen terminates Alaunos license agreement, regains all rights
Terminated Amended and Restated License Agreement with Alaunos effective Oct 4, 2024.
Precigen SVP of Intellectual Property Affairs Jeffrey Perez to depart Nov 1, 2024
Jeffrey Perez, SVP of Intellectual Property Affairs, will separate from Precigen effective November 1, 2024.
Precigen grants PSUs tied to PRGN-2012 BLA milestones to named execs
Target PSUs granted: CEO Helen Sabzevari 1,650,000; CFO Harry Thomasian 250,000; COO Rutul Shah 250,000; CLO Donald Lehr 108,000.
Precigen Q2 net loss widens to $58.8M; pivots to PRGN-2012 with BLA submission planned H2 2024
Q2 2024 net loss of $58.8M ($0.23/share) vs $20.3M loss a year ago; includes impairment charge of $32.9M.
Precigen raises ~$31.4M net in underwritten public offering of 35.3M shares at $0.85
Precigen entered into underwriting agreement with Stifel for offering of 35,294,118 shares at $0.85/share.
Precigen reports $19.5M cash, $32.9M impairment, $30M offering, >20% workforce cut
Preliminary cash $19.5M at June 30, 2024; non-cash impairment charges ~$32.9M and severance ~$3.0M in Q2/Q3.
Precigen elects Nancy Howell Agee to board; shareholders approve 2M share increase in incentive plan
Dean Mitchell's term ended July 5, 2024; he did not stand for re-election, no disagreement cited.
Precigen Q1 net loss $23.7M, revenue down 43%; PRGN-2012 BLA submission on track for H2 2024
Net loss $23.7M ($0.10 EPS) vs $22.7M; total revenue down 43% YoY to approx. $1.06M.
Precigen reports FY2023 loss of $95.9M; plans BLA submission for PRGN-2012 in H2 2024
FY2023 revenue $6.2M, down 77% YoY; net loss $95.9M ($0.39 loss per share).
Precigen enters continuing employment agreements with CFO and COO providing 12-month severance
CFO Harry Thomasian Jr. and COO Rutul R. Shah entered continuing employment agreements approved Feb 2, 2024.
Precigen announces PRGN-2012 Phase 2 data expected Q2 2024; BLA submission planned H2 2024
PRGN-2012 Phase 2 pivotal data in RRP anticipated Q2 2024; BLA submission under accelerated approval H2 2024.
Precigen Q3 2023 loss per share $0.08; FDA agrees PRGN-2012 study pivotal for BLA
Cash and investments $79.0M as of Sep 30, 2023; cash runway projected into 2025.
FDA confirms PRGN-2012 Phase 1/2 study as pivotal for accelerated approval; cash runway into 2025
FDA confirmed ongoing Phase 1/2 single-arm study of PRGN-2012 for RRP as pivotal for accelerated approval; no placebo trial needed.
Precigen shareholders approve 2023 Omnibus Incentive Plan at Annual Meeting
All nine director nominees elected; Randal Kirk received 146.7M votes for.
Precigen Q1 loss narrows to $22.7M; raises $72.8M in offering; pipeline advances
Revenue fell 66% YoY; Q1 operating loss $22.7M ($0.10 EPS) vs $23.9M ($0.12 EPS) in Q1 2022.
Precigen enters amended license with Alaunos for TCR products; Alaunos pays $75K annual fee
Precigen grants Alaunos exclusive, worldwide, royalty-free license for T-cell receptor products targeting neoantigens and HPV.
Precigen reports minimal SVB exposure, reaffirms cash runway into late 2024
Company has minimal exposure to Silicon Valley Bank after its closure and FDIC receivership.
Precigen reports Q4 2022 loss of $22.2M; cash $99.7M; clinical progress in RRP and AML
Q4 loss from continuing ops $22.2M ($0.11/sh); full year loss $79.8M ($0.40/sh).
Precigen (PGEN) prices public offering of 42.9M shares at $1.75, net ~$71.2M
Underwriting agreement with J.P. Morgan Securities as lead for 42,857,143 firm shares at $1.75/share.
Precigen reports positive Phase 1 PRGN-2012 data: 50% complete response in RRP patients
50% of RRP patients at Dose Level 2 achieved Complete Response, requiring no post-treatment surgeries.
Precigen reports pipeline progress and R&D Day for PRGN-2012 data on Jan 24, 2023
PRGN-2012 Phase 2 enrollment rapid; 20 patients enrolled; R&D Day Jan 24 to share Phase 1 data.
Precigen Q3 net loss $7.6M; cash $153.8M; retired $144M convertible notes
Net loss from continuing ops $7.6M ($0.04/sh) vs $26.3M loss; total revenues up $13.4M (>200%) YoY.
Precigen appoints Rutul R. Shah as COO, effective Oct 1, 2022
Rutul R. Shah, previously VP Head of Operations, appointed COO; newly created role.
Precigen completes $170M sale of Trans Ova Genetics; pro forma shows $213M cash
Closed sale of 100% of Trans Ova to Spring Bidco LLC for $170M; net cash proceeds ~$169.5M.
Precigen completes sale of Trans Ova Genetics for $170M upfront plus up to $10M earn-out
Sale closed on August 18, 2022; buyer is Spring Bidco LLC (URUS). Net proceeds ~$169.5M after adjustments.
Precigen enters $100M ATM equity offering with Cantor Fitzgerald
Up to $100M of common stock may be sold at-the-market through Cantor Fitzgerald as agent.
Precigen Q2 loss from cont. ops $26.1M; divests Trans Ova Genetics for $170M
Loss from continuing ops $26.1M ($0.13 loss per share) vs $30.9M loss in Q2 2021.
Precigen wins arbitration, to acquire membership interests for $7M
Arbitration panel adopted Precigen's proposed terms for disputes with investors in Intrexon Energy Partners entities.
Precigen agrees to sell Trans Ova Genetics to URUS for $170M upfront cash plus $10M earn-out
Total consideration up to $180M: $170M cash at closing plus $10M earn-out based on 2022-2023 performance.
Precigen shareholders elect all directors, approve equity plan amendments at annual meeting
All 10 director nominees elected; Helen Sabzevari top vote-getter with 121.2M votes.
Precigen Q1 revenue $32M (+31% YoY); Fast Track for PRGN-3006 in AML
Total revenues $32.0M, up 31% vs $24.5M YoY; net loss $19.3M ($0.10/share).
Precigen Q4 net loss $25M, FY loss $96.8M; $163.7M cash; clinical progress
Q4 net loss from continuing ops $25.0M ($0.13/sh) vs $39.7M ($0.22/sh) year ago; full-year net loss $96.8M ($0.49/sh) vs $103.8M.
Precigen reports Phase 1 data: 50% AML ORR, 40% HPV ORR; cash $181.3M
50% ORR (3/6) in relapsed/refractory AML at low dose levels of PRGN-3006 UltraCAR-T in Phase 1 lymphodepletion cohort.
Precigen appoints Harry Thomasian Jr. as CFO effective Oct 18, 2021
Harry Thomasian Jr., 59, appointed CFO, effective October 18, 2021; succeeds interim CFO James V. Lambert.
On September 23, 2024, Precigen, Inc. (the “Company”) announced the separation from employment of Jeffrey Perez, Senior Vice President, Intellectual Property Affairs, effective November 1, 2024.
As described under Item 5.07 below, at the 2024 Annual Meeting, Nancy Howell Agee was elected to the Board, effective as of July 5, 2024.
As previously disclosed in the Proxy Statement, Dean Mitchell did not stand for re-election at 2024 Annual Meeting. Accordingly, Mr. Mitchell’s term on the Board ended effective as of July 5, 2024.
On September 15, 2022, the Board of Directors (the “Board”) of Precigen, Inc. (the “Company”) approved the appointment of Rutul R. Shah, currently the Company’s Vice President, Head of Operations and Portfolio, to serve as Chief Operating Officer of the Company, effective October 1, 2022.
James V. Lambert, who has served as interim principal accounting officer of the Company since Mr. Osborne's resignation, will step down from that position effective upon Mr. Thomasian's start date, and will continue to serve as Executive Director, Finance for PGEN Therapeutics, Inc., a wholly owned subsidiary of the Company.
On October 12, 2021, Precigen, Inc. (the “Company”), announced that Harry Thomasian Jr., age 59, was appointed Chief Financial Officer of the Company, effective October 18, 2021.
Max materiality 0.90 · Median 0.70 · Most common event other_material